The company manufactures active pharmaceutical ingredients (APIs) and drug intermediates, such as Metformin and Mefenamic Acid, while also operating a significant trading business in industrial solvents and chemicals.
The company lacks a durable moat, evidenced by razor-thin net margins (1.3%) and low returns on capital (8.7% ROCE) that do not exceed the cost of capital. The business is primarily a commodity trading operation with a small manufacturing component, offering no unique pricing power or scale advantage.
Capital allocation is poor, characterized by significant non-interest-bearing loans to directors and related parties (over 10 crore INR in FY24) and reinvestment into low-return assets. The company frequently raises capital through preferential allotments while maintaining low profitability and negative EPS growth.
The business collapsed as the thin manufacturing veneer was stripped away, revealing a low-margin commodity trading house that served primarily as a personal piggy bank for its directors. Over five years, the persistent diversion of capital through interest-free loans to the promoter family starved the core operations of necessary working capital, while the lack of internal accounting controls led to a terminal breakdown in trust with lenders. As the gap between reported book values and actual bank stock statements widened, credit lines were frozen, and the company was unable to service its debt or fund its inefficient cash conversion cycle, resulting in a total loss of shareholder value.
RichFakir rates Aarey Drugs & Pharmaceuticals Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Aarey Drugs & Pharmaceuticals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Aarey Drugs & Pharmaceuticals Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Aarey Drugs & Pharmaceuticals Ltd's fair value is about ₹16 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →